| Study |
Reference |
|
Battino (Vigabatrin) (Epilepsy), 2024
|
Battino Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol 2024; 81:481-489 Tomson Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530-538 Tomson T Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
|
|
Christensen (Vigabatrin) (Epilepsy) (Controls exposed to LTG), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849
|
|
Christensen (Vigabatrin) (Epilepsy) (Controls unexposed, general population), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849
|
|
Källén (Vigabatrin) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013
|
Källén The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013; 6:1221-86 Wide Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93:174-6
|
|
Källén (Vigabatrin) (Controls unexposed, NOS) (Indications NOS), 2013
|
Källén The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013; 6:1221-86
|
|
Kilic (Vigabatrin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Kilic Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014; 55:1714-21
|
|
Kilic (Vigabatrin) (Controls unexposed NOS) (Mixed indications), 2014
|
Kilic Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014; 55:1714-21
|
|
Kilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014
|
Kilic Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014; 55:1714-21
|
|
Mawer (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2010
|
Mawer Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010; 19:112-9
|
|
Mawer (Vigabatrin) (Controls unexposed, disease free), 2010
|
Mawer Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010; 19:112-9
|
|
Mawer (Vigabatrin) (Controls unexposed, sick), 2010
|
Mawer Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010; 19:112-9
|
|
Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006
|
Morrow Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77:193-8
|
|
Morrow (Vigabatrin) (Controls unexposed, sick), 2006
|
Morrow Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77:193-8
|
|
Vajda (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2019
|
Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014; 130:234-8
|
|
Vajda (Vigabatrin) (Controls unexposed, sick), 2019
|
Vajda Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013; 128:228-34 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11 Vajda The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014; 130:234-8
|
